Cargando…

Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma

The histological transformation from lung squamous cell carcinoma (LUSC) to lung adenocarcinoma (LUAD) and p. N771delinsGF mutations in EGFR exon 20 (ex20) are exceedingly rare in non–small cell lung carcinoma (NSCLC). EGFR ex20 mutations are insensitive to EGFR tyrosine kinase inhibitors in NSCLC....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Lingling, Liu, Yanyang, Gao, Honglin, Liu, Jiewei, Zhou, Qinghua, Luo, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784849/
https://www.ncbi.nlm.nih.gov/pubmed/35083213
http://dx.doi.org/10.3389/fcell.2021.755135
_version_ 1784638830528167936
author Zhu, Lingling
Liu, Yanyang
Gao, Honglin
Liu, Jiewei
Zhou, Qinghua
Luo, Feng
author_facet Zhu, Lingling
Liu, Yanyang
Gao, Honglin
Liu, Jiewei
Zhou, Qinghua
Luo, Feng
author_sort Zhu, Lingling
collection PubMed
description The histological transformation from lung squamous cell carcinoma (LUSC) to lung adenocarcinoma (LUAD) and p. N771delinsGF mutations in EGFR exon 20 (ex20) are exceedingly rare in non–small cell lung carcinoma (NSCLC). EGFR ex20 mutations are insensitive to EGFR tyrosine kinase inhibitors in NSCLC. Here, we present a 76-year-old male smoker harboring LUAD with a novel p. N771delinsGF deletion/insertion mutation in EGFR ex20 transdifferentiating from advanced LUSC after chemoradiotherapy. The patient presented reduced hydrothorax and relieved tightness with the treatment of nivolumab plus docetaxel and carboplatin after the failure of second-line chemotherapy. The case highlights the importance of rebiopsy and molecular retesting after the progression of lung cancer and supports the idea that the combination of immune checkpoint blockade and chemotherapy may be an attractive option for patients with EGFR ex20 mutations associated with LUSC–LUAD transformation.
format Online
Article
Text
id pubmed-8784849
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87848492022-01-25 Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma Zhu, Lingling Liu, Yanyang Gao, Honglin Liu, Jiewei Zhou, Qinghua Luo, Feng Front Cell Dev Biol Cell and Developmental Biology The histological transformation from lung squamous cell carcinoma (LUSC) to lung adenocarcinoma (LUAD) and p. N771delinsGF mutations in EGFR exon 20 (ex20) are exceedingly rare in non–small cell lung carcinoma (NSCLC). EGFR ex20 mutations are insensitive to EGFR tyrosine kinase inhibitors in NSCLC. Here, we present a 76-year-old male smoker harboring LUAD with a novel p. N771delinsGF deletion/insertion mutation in EGFR ex20 transdifferentiating from advanced LUSC after chemoradiotherapy. The patient presented reduced hydrothorax and relieved tightness with the treatment of nivolumab plus docetaxel and carboplatin after the failure of second-line chemotherapy. The case highlights the importance of rebiopsy and molecular retesting after the progression of lung cancer and supports the idea that the combination of immune checkpoint blockade and chemotherapy may be an attractive option for patients with EGFR ex20 mutations associated with LUSC–LUAD transformation. Frontiers Media S.A. 2022-01-10 /pmc/articles/PMC8784849/ /pubmed/35083213 http://dx.doi.org/10.3389/fcell.2021.755135 Text en Copyright © 2022 Zhu, Liu, Gao, Liu, Zhou and Luo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Zhu, Lingling
Liu, Yanyang
Gao, Honglin
Liu, Jiewei
Zhou, Qinghua
Luo, Feng
Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma
title Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma
title_full Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma
title_fullStr Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma
title_full_unstemmed Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma
title_short Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma
title_sort case report: partial response following nivolumab plus docetaxel in a patient with egfr exon 20 deletion/insertion (p.n771delinsgf) mutant lung adenocarcinoma transdifferentiated from squamous cell carcinoma
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784849/
https://www.ncbi.nlm.nih.gov/pubmed/35083213
http://dx.doi.org/10.3389/fcell.2021.755135
work_keys_str_mv AT zhulingling casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma
AT liuyanyang casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma
AT gaohonglin casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma
AT liujiewei casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma
AT zhouqinghua casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma
AT luofeng casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma